July 10, 2025
| Today’s news and insights for biopharma leaders
The agency disclosed a tranche of more than 200 complete response letters from the past five years, but only those involving medicines that it later cleared.
|
The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and autoimmune conditions, too.
|
The biotech is taking inspiration from cystic fibrosis treatment and applying a similar approach to developing "corrector" and "potentiator" medicines for the kidney disease.
|
The approval comes amid regulatory upheaval under HHS head Robert F. Kennedy Jr., who has pushed for changes around mRNA vaccines in particular.
|
UPDATED
Merck’s $10 billion acquisition of Verona Pharma follows about one month after Sanofi agreed to pay $9.1 billion for Blueprint, bucking a trend the past year to smaller deals.
|
Improve launch success and optimize investments
|
|
From Our Library
Playbook
Custom content for Premier Research
|
Playbook
Custom content for Medrio
|
Webinar - on demand
Custom content for PPD FSP solutions
|
Trendline
Supported by Quest Diagnostics
|
Trendline
Supported by Marken
|
View all resources
What We’re Readi | 
